U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C22H38O5
Molecular Weight 382.535
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 4
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of MISOPROSTOL

SMILES

CCCCC(C)(C/C(/[H])=C(\[H])/[C@]1([H])[C@@]([H])(CCCCCCC(=O)OC)C(=O)C[C@@]1([H])O)O

InChI

InChIKey=OJLOPKGSLYJEMD-URPKTTJQSA-N
InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/cdi/misoprostol.html

Misoprostol is a prostaglandin E1 (PGE1) analogue used for the treatment and prevention of stomach ulcers. When administered, misoprostol stimulates increased secretion of the protective mucus that lines the gastrointestinal tract and increases mucosal blood flow, thereby increasing mucosal integrity. It is sometimes co-prescribed with non-steroidal anti-inflammatory drugs (NSAIDs) to prevent the occurrence of gastric ulceration, a common adverse effect of the NSAIDs. Misoprostol seems to inhibit gastric acid secretion by a direct action on the parietal cells through binding to the prostaglandin receptor. The activity of this receptor is mediated by G proteins which normally activate adenylate cyclase. The indirect inhibition of adenylate cyclase by Misoprostol may be dependent on guanosine-5’-triphosphate (GTP). The significant cytoprotective actions of misoprostol are related to several mechanisms. These include: 1. Increased secretion of bicarbonate, 2. Considerable decrease in the volume and pepsin content of the gastric secretions, 3. It prevents harmful agents from disrupting the tight junctions between the epithelial cells which stops the subsequent back diffusion of H+ ions into the gastric mucosa, 4. Increased thickness of mucus layer, 5. Enhanced mucosal blood flow as a result of direct vasodilatation, 6. Stabilization of tissue lysozymes/vascular endothelium, 7. Improvement of mucosal regeneration capacity, and 8. Replacement of prostaglandins that have been depleted as a result of various insults to the area. Misoprostol has also been shown to increase the amplitude and frequency of uterine contractions during pregnancy via selective binding to the EP-2/EP-3 prostanoid receptors. Misoprostol is indicated for the treatment of ulceration (duodenal, gastric and NSAID induced) and prophylaxis for NSAID induced ulceration. Misoprostol is also indicated for other uses that are not approved in Canada, including the medical termination of an intrauterine pregnancy used alone or in combination with methotrexate, as well as the induction of labour in a selected population of pregnant women with unfavourable cervices. This indication is avoided in women with prior uterine surgery or cesarean surgery due to an increased risk of possible uterine rupture. Misoprostol is also used for the prevention or treatment of serious postpartum hemorrhage. Misoprostol is sold under the brandname Cytotec among others.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.74 µM [EC50]
124.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Cytotec

Approved Use

Cytotec (misoprostol) is indicated for reducing the risk of NSAID (nonsteroidal antiinflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer.

Launch Date

5.9909761E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.683 ng/mL
800 μg single, oral
dose: 800 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
1.361 ng/mL
800 μg single, buccal
dose: 800 μg
route of administration: Buccal
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
2.439 ng/mL
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
811 pg/mL
300 μg single, oral
dose: 300 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2.019 ng × h/mL
800 μg single, oral
dose: 800 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
2.073 ng × h/mL
800 μg single, buccal
dose: 800 μg
route of administration: Buccal
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
3.209 ng × h/mL
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
417 pg × h/mL
300 μg single, oral
dose: 300 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.04 h
800 μg single, oral
dose: 800 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
0.837 h
800 μg single, buccal
dose: 800 μg
route of administration: Buccal
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
0.854 h
800 μg single, sublingual
dose: 800 μg
route of administration: Sublingual
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
0.5 h
300 μg single, oral
dose: 300 μg
route of administration: Oral
experiment type: SINGLE
co-administered:
MISOPROSTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
MISOPROSTOL serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
12 mg single, oral
Overdose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
healthy, adolescent
n = 1
Health Status: healthy
Condition: induce abortion
Age Group: adolescent
Sex: F
Population Size: 1
Sources:
Disc. AE: Multiorgan failure...
AEs leading to
discontinuation/dose reduction:
Multiorgan failure (grade 5, 1 patient)
Sources:
8400 mg single, oral
Overdose
Dose: 8400 mg
Route: oral
Route: single
Dose: 8400 mg
Sources:
healthy, mean 28.8 years
n = 1
Health Status: healthy
Condition: induce abortion
Age Group: mean 28.8 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Abdominal pain, Vomiting...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (1 patient)
Vomiting (1 patient)
Diarrhea (1 patient)
Sources:
50 ug 4 times / day steady, vaginal
Recommended
Dose: 50 ug, 4 times / day
Route: vaginal
Route: steady
Dose: 50 ug, 4 times / day
Sources:
healthy, mean 28.8 years
n = 172
Health Status: healthy
Condition: live term single cephalic fetus for indicated labor induction
Age Group: mean 28.8 years
Sex: F
Population Size: 172
Sources:
Other AEs: Diarrhea, Nausea...
Other AEs:
Diarrhea (1.7%)
Nausea (9.3%)
Vomiting (14%)
Sources:
50 ug 6 times / day steady, oral
Recommended
Dose: 50 ug, 6 times / day
Route: oral
Route: steady
Dose: 50 ug, 6 times / day
Sources:
healthy, mean 29.1 years
n = 167
Health Status: healthy
Condition: live term single cephalic fetus for indicated labor induction
Age Group: mean 29.1 years
Sex: F
Population Size: 167
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (9.6%)
Vomiting (17.4%)
Sources:
400 ug single, oral
Dose: 400 ug
Route: oral
Route: single
Dose: 400 ug
Co-administed with::
mifepristone(600 mg)
Sources:
healthy, mean 30.2 years
n = 92
Health Status: healthy
Condition: induce abortion
Age Group: mean 30.2 years
Sex: F
Population Size: 92
Sources:
Other AEs: Bleeding, Vomiting...
Other AEs:
Bleeding (68.2%)
Vomiting (7.6%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Multiorgan failure grade 5, 1 patient
Disc. AE
12 mg single, oral
Overdose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
healthy, adolescent
n = 1
Health Status: healthy
Condition: induce abortion
Age Group: adolescent
Sex: F
Population Size: 1
Sources:
Abdominal pain 1 patient
Disc. AE
8400 mg single, oral
Overdose
Dose: 8400 mg
Route: oral
Route: single
Dose: 8400 mg
Sources:
healthy, mean 28.8 years
n = 1
Health Status: healthy
Condition: induce abortion
Age Group: mean 28.8 years
Sex: F
Population Size: 1
Sources:
Diarrhea 1 patient
Disc. AE
8400 mg single, oral
Overdose
Dose: 8400 mg
Route: oral
Route: single
Dose: 8400 mg
Sources:
healthy, mean 28.8 years
n = 1
Health Status: healthy
Condition: induce abortion
Age Group: mean 28.8 years
Sex: F
Population Size: 1
Sources:
Vomiting 1 patient
Disc. AE
8400 mg single, oral
Overdose
Dose: 8400 mg
Route: oral
Route: single
Dose: 8400 mg
Sources:
healthy, mean 28.8 years
n = 1
Health Status: healthy
Condition: induce abortion
Age Group: mean 28.8 years
Sex: F
Population Size: 1
Sources:
Diarrhea 1.7%
50 ug 4 times / day steady, vaginal
Recommended
Dose: 50 ug, 4 times / day
Route: vaginal
Route: steady
Dose: 50 ug, 4 times / day
Sources:
healthy, mean 28.8 years
n = 172
Health Status: healthy
Condition: live term single cephalic fetus for indicated labor induction
Age Group: mean 28.8 years
Sex: F
Population Size: 172
Sources:
Vomiting 14%
50 ug 4 times / day steady, vaginal
Recommended
Dose: 50 ug, 4 times / day
Route: vaginal
Route: steady
Dose: 50 ug, 4 times / day
Sources:
healthy, mean 28.8 years
n = 172
Health Status: healthy
Condition: live term single cephalic fetus for indicated labor induction
Age Group: mean 28.8 years
Sex: F
Population Size: 172
Sources:
Nausea 9.3%
50 ug 4 times / day steady, vaginal
Recommended
Dose: 50 ug, 4 times / day
Route: vaginal
Route: steady
Dose: 50 ug, 4 times / day
Sources:
healthy, mean 28.8 years
n = 172
Health Status: healthy
Condition: live term single cephalic fetus for indicated labor induction
Age Group: mean 28.8 years
Sex: F
Population Size: 172
Sources:
Vomiting 17.4%
50 ug 6 times / day steady, oral
Recommended
Dose: 50 ug, 6 times / day
Route: oral
Route: steady
Dose: 50 ug, 6 times / day
Sources:
healthy, mean 29.1 years
n = 167
Health Status: healthy
Condition: live term single cephalic fetus for indicated labor induction
Age Group: mean 29.1 years
Sex: F
Population Size: 167
Sources:
Nausea 9.6%
50 ug 6 times / day steady, oral
Recommended
Dose: 50 ug, 6 times / day
Route: oral
Route: steady
Dose: 50 ug, 6 times / day
Sources:
healthy, mean 29.1 years
n = 167
Health Status: healthy
Condition: live term single cephalic fetus for indicated labor induction
Age Group: mean 29.1 years
Sex: F
Population Size: 167
Sources:
Bleeding 68.2%
400 ug single, oral
Dose: 400 ug
Route: oral
Route: single
Dose: 400 ug
Co-administed with::
mifepristone(600 mg)
Sources:
healthy, mean 30.2 years
n = 92
Health Status: healthy
Condition: induce abortion
Age Group: mean 30.2 years
Sex: F
Population Size: 92
Sources:
Vomiting 7.6%
400 ug single, oral
Dose: 400 ug
Route: oral
Route: single
Dose: 400 ug
Co-administed with::
mifepristone(600 mg)
Sources:
healthy, mean 30.2 years
n = 92
Health Status: healthy
Condition: induce abortion
Age Group: mean 30.2 years
Sex: F
Population Size: 92
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Misoprostol in the treatment of duodenal ulcer. A multicenter double-blind placebo-controlled study.
1985 Nov
Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy.
1986 Aug
The effect of misoprostol on base-line and stimulated acid secretion and on gastrin and histamine release in the totally isolated, vascularly perfused rat stomach.
1988 Aug
Neurosensory adverse effects after phenylbutazone and misoprostol combined treatment.
1989 Nov 25
Neurological adverse effects of naproxen and misoprostol combination.
1990 Oct
Overall safety of Arthrotec.
1992
Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect.
1992 Dec
Brazil investigates drug's possible link with birth defects.
1994 Sep 24
Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.
1995 Apr
The effect of misoprostol on indomethacin-induced renal dysfunction in well-compensated cirrhosis.
1995 Jul
The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.
1995 Sep
Misoprostol associated autonomic dysreflexia in a traumatic tetraplegic patient.
1996 Feb
Extemporaneous preparation of misoprostol gel for cervical ripening: a randomized trial.
1997 Dec
A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second-trimester abortion.
1997 Dec
Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
1997 Sep
Use of misoprostol during pregnancy and Möbius' syndrome in infants.
1998 Jun 25
Timing of pain and bleeding after mifepristone-induced abortion.
2000 Dec
Prenatal exposure to misoprostol and vascular disruption defects: a case-control study.
2000 Dec 11
The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.
2000 Jan 17
Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal.
2001 Mar 2
Side-effects of oral misoprostol in the third stage of labour--a randomised placebo-controlled trial.
2001 May
High rates of cramping with misoprostol administration for intrauterine insemination.
2001 May
Buccal versus intravaginal misoprostol administration for cervical ripening.
2002 Feb
Having an abortion using mifepristone and home misoprostol: a qualitative analysis of women's experiences.
2002 Jan-Feb
Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol.
2002 May
Cognitive decline in administration of the nonsteroidal antiinflammatory drug loxoprofen with misoprostol in a 91-year-old Japanese woman.
2002 Oct
Effect of misoprostol and indomethacin on cyclooxygenase induction and eicosanoid production in carrageenan-induced air pouch inflammation in rats.
2002 Sep
Möbius sequence in children exposed in utero to misoprostol: neuropathological study of three cases.
2003 Dec
[Moebius syndrome due to the use of misoprostol. Case report].
2003 Jun
WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.
2004 Jul
Poland-Möbius syndrome and cocaine abuse: a relook at vascular etiology.
2005 Apr
Functional role of prostacyclin receptor in rat dorsal root ganglion neurons.
2005 Nov 18
Early dental management of patients with Mobius syndrome.
2006 Nov
Comparison of antinociceptive efficacy and gastroprotection between celecoxib and diclofenac plus misoprostol in rats.
2007
Comparative study of misoprostol vs dinoprostone for induction of labour.
2007 Jan-Mar
Misoprostol and pregnancy: risk of malformations.
2008 Apr
Cryptogenic stroke in the setting of intravaginal prostaglandin therapy for elective abortion.
2008 May
Prostaglandin analogue misoprostol attenuates neurotoxin 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death in differentiated PC12 cells.
2008 Nov 25
Improved antiulcer and anticancer properties of a trans-resveratrol analog in mice.
2009 Mar
Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling.
2009 Mar 16
Acute coronary artery vasospasm associated with misoprostol for termination of pregnancy.
2010
Protective effect of anacardic acids from cashew (Anacardium occidentale) on ethanol-induced gastric damage in mice.
2010 Jan 5
Moebius syndrome and holoprosencephaly following exposure to misoprostol.
2010 Nov
Effects of misoprostol on cisplatin-induced renal damage in rats.
2011 Jul
Synthesis and biological evaluation of novel thiazolidinedione analogues as 15-hydroxyprostaglandin dehydrogenase inhibitors.
2011 Jul 28
Patents

Patents

Sample Use Guides

The recommended adult oral dose of Cytotec (Misoprostol) for reducing the risk of NSAID-induced gastric ulcers is 200 mcg four times daily with food. If this dose cannot be tolerated, a dose of 100 mcg can be used
Route of Administration: Oral
Antigen-evoked secretion of IFN-gamma by influenza hemagglutinin-specific mouse lymph node Th1 cells, that also express EP3Rs and EP4Rs, was increased a maximum of 10-fold by 10(-9) M misoprostol.
Name Type Language
MISOPROSTOL
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
PROST-13-EN-1-OIC ACID, 11,16-DIHYDROXY-16-METHYL-9-OXO-, METHYL ESTER, (11.ALPHA.,13E)-(+/-)-
Common Name English
MISOPROSTOL [MART.]
Common Name English
MISOPROSTOL [HSDB]
Common Name English
CYTOTEC
Brand Name English
SC-29333
Code English
MISOPROSTOL [USP-RS]
Common Name English
MISOPROSTOL COMPONENT OF ARTHROTEC
Common Name English
MISOPROSTOL [MI]
Common Name English
MISOPROSTOL [INN]
Common Name English
MISOPROSTOL [ORANGE BOOK]
Common Name English
MISOPROSTOL [USP MONOGRAPH]
Common Name English
MISOPROSTOL [VANDF]
Common Name English
(+/-)-METHYL (1R,2R,3R)-3-HYDROXY-2-((E)-(4RS)-4-HYDROXY-4-METHYL-1-OCTENYL)-5-OXOCYCLOPENTANEHEPTANOATE
Systematic Name English
MISOPROSTOL [USAN]
Common Name English
MISOPROSTOL [WHO-DD]
Common Name English
MISOPROSTOL [EP MONOGRAPH]
Common Name English
ARTHROTEC COMPONENT MISOPROSTOL
Brand Name English
MISOPROSTOL [JAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000007710
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
WHO-ATC G02AD06
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 22.1 (MIF/MIS)
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
NDF-RT N0000007710
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
WHO-ATC A02BB01
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
LIVERTOX 644
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
NDF-RT N0000175785
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
NCI_THESAURUS C2080
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
WHO-VATC QA02BB01
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
FDA ORPHAN DRUG 186604
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
NCI_THESAURUS C29701
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
WHO-VATC QM01AE56
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
NDF-RT N0000007710
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
NCI_THESAURUS C78568
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
WHO-ATC M01AE56
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
WHO-VATC QG02AD06
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 22.1
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C1313
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
EVMPD
SUB08998MIG
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
LACTMED
Misoprostol
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
MESH
D016595
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
MERCK INDEX
M7563
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
1817
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
HSDB
3573
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
INN
5154
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
IUPHAR
1936
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
WIKIPEDIA
MISOPROSTOL
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
RXCUI
42331
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY RxNorm
PUBCHEM
5282381
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
DRUG BANK
DB00929
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
CAS
59122-46-2
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
ChEMBL
CHEMBL606
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
FDA UNII
0E43V0BB57
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY
USP_CATALOG
1444300
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY USP-RS
EPA CompTox
59122-46-2
Created by admin on Fri Jun 25 20:56:25 UTC 2021 , Edited by admin on Fri Jun 25 20:56:25 UTC 2021
PRIMARY